K. Vanshylla

The paper reverts mutations in SARS-CoV-2 antibodies to study SHM's impact on neutralization, finding that some mutations are critical for neutralizing Omicron variants.

This study evaluates the neutralization sensitivity of the SARS-CoV-2 BA.2.75 sublineage compared to other variants, finding it less resistant to antibodies than BA.4/5 but more than BA.2.

This study evaluates antibody escape from Omicron sublineages by testing serum and monoclonal antibody activity against BA.1, BA.2, BA.2.12.1, and BA.4/5, revealing increased resistance in BA.4/5 and identifying promising neutralizing antibodies.

The paper analyzes B cell immunity in unexposed adults and finds no substantial pre-existing antibody or B cell response to SARS-CoV-2.

This paper describes a monoclonal antibody, DZIF-10c, that effectively neutralizes SARS-CoV-2 and its variants when administered intranasally to mice, offering potential for topical treatment.

This study examines the kinetics and correlates of the SARS-CoV-2 neutralizing antibody response in 963 recovered individuals over 10 months, finding variations in antibody persistence and identifying factors predicting neutralizing activity.

This paper introduces a novel humanized mouse model, CD34T+, which is highly permissive to mucosal HIV-1 infection and can be prevented by broadly neutralizing antibodies.

The paper models HIV-1 escape dynamics from broadly neutralizing antibodies using clinical trial data, identifying fitness factors that predict viral reproduction rates and resistance tradeoffs.

This study isolates potent SARS-CoV-2-neutralizing antibodies from COVID-19 patients as early as 8 days post-diagnosis and identifies precursor B cells in healthy individuals.